NEW YORK, March 1, 2017 /PRNewswire/ --
Stock-Callers.com shifts focus on four equities in the Healthcare sector, which are Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), Apricus Biosciences Inc. (NASDAQ: APRI), and Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP). According to Deloitte's 2017 Global Health Care Sector Outlook the challenges of providing and funding healthcare around the world are likely to continue this year due to the rising demands and associated spending of the aging population, the growing prevalence of chronic diseases and comorbidities, the development of costly clinical innovations, increasing patient expectations, and continued economic turbulence. Register now and get full and free access to our downloadable research reports on these stocks at:
http://stock-callers.com/registration
Synergy Pharma
On Tuesday, shares in New York headquartered Synergy Pharmaceuticals Inc. recorded a trading volume of 6.68 million shares, which was above their three months average volume of 6.57 million shares. The stock ended the session 2.20% lower at $5.79. The Company's shares have gained 5.95% in the previous three months. The stock is trading 16.84% above its 200-day moving average. Moreover, shares of Synergy Pharma, which focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases, have a Relative Strength Index (RSI) of 45.90. On February 07th, 2017, Synergy Pharmaceuticals announced that the American Journal of Gastroenterology has published detailed results from a pivotal Phase 3 trial that demonstrated the efficacy and safety of TRULANCE™ (plecanatide) for the treatment of adults with chronic idiopathic constipation (CIC).
On January 19th, 2017, TRULANCE was approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with CIC. TRULANCE is the first drug designed to replicate the function of uroguanylin, a naturally occurring and endogenous human gastrointestinal peptide that is thought to stimulate fluid secretion within the changing pH environment of the intestine. Access our complete research report on SGYP for free at:
http://stock-callers.com/registration/?symbol=SGYP
Novo Nordisk
Bagsvaerd, Denmark headquartered Novo Nordisk A/S' stock closed the day 1.15% lower at $35.33 with a total trading volume of 2.89 million shares. The Company's shares have advanced 10.13% over the previous three months. The stock is trading 0.17% below its 50-day moving average. Additionally, shares of Novo Nordisk, which engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide, have an RSI of 52.02.
On 28th, February 2017, Novo Nordisk announced the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labor, and Welfare for semaglutide, a new glucagon-like peptide-1 (GLP-1) analogue administrated once-weekly, for the treatment of adults with type-2 diabetes. The Japanese filing follows the recent once-weekly semaglutide regulatory submissions to the US FDA, the European Medicines Agency (EMA), Health Canada, and SwissMedic. The complimentary research report on NVO can be downloaded at:
http://stock-callers.com/registration/?symbol=NVO
Apricus Biosciences
Shares in San Diego, California headquartered Apricus Biosciences Inc. recorded a trading volume of 274,452 shares. The stock ended yesterday's trading session 7.94% lower at $2.90. The Company's shares have surged 21.85% in the past month, 89.54% in the previous three months, and 123.08% on an YTD basis. The stock is trading above its 50-day moving average by 37.60%. Furthermore, shares of Apricus Biosciences, which focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology, have an RSI of 58.74.
On February 09th, 2017, Apricus Biosciences announced that on February 08th, 2017, it was notified that the NASDAQ Hearings Panel has granted the Company`s request for continued listing on NASDAQ pursuant to an extension through May 30th, 2017, by which date the Company must evidence full compliance with all applicable criteria for continued listing on the NASDAQ Capital Market, including the $2.5 million stockholders` equity requirement. Register for free on Stock-Callers.com and get access to the latest PDF format report on APRI at:
http://stock-callers.com/registration/?symbol=APRI
Sucampo Pharma
Rockville, Maryland headquartered Sucampo Pharmaceuticals Inc.'s stock finished Tuesday's session 4.08% lower at $11.75. A total volume of 1.23 million shares was traded, which was above their three months average volume of 1.20 million shares. The Company's shares have advanced 5.86% in the last one month. The stock is trading below its 200-day moving average by 5.39%. Additionally, shares of Sucampo Pharma, which focuses on the research and development of proprietary drugs for the treatment of gastrointestinal, ophthalmic, autoimmune, and oncology-based inflammatory disorders in the US, Japan, Switzerland, and internationally, have an RSI of 47.60.
On February 23rd, 2017, Sucampo Pharmaceuticals announced that it will host its Q4 and full year 2016 financial results teleconference and webcast at 8:30 a.m. ET on Wednesday, March 08th, 2017. The press release announcing the financial results and operating highlights is expected to be released before the opening of capital markets on the same day. Download your free research report on SCMP at:
http://stock-callers.com/registration/?symbol=SCMP
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Advertisement
Stock-Callers.com shifts focus on four equities in the Healthcare sector, which are Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), Apricus Biosciences Inc. (NASDAQ: APRI), and Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP). According to Deloitte's 2017 Global Health Care Sector Outlook the challenges of providing and funding healthcare around the world are likely to continue this year due to the rising demands and associated spending of the aging population, the growing prevalence of chronic diseases and comorbidities, the development of costly clinical innovations, increasing patient expectations, and continued economic turbulence. Register now and get full and free access to our downloadable research reports on these stocks at:
Advertisement
http://stock-callers.com/registration
Synergy Pharma
On Tuesday, shares in New York headquartered Synergy Pharmaceuticals Inc. recorded a trading volume of 6.68 million shares, which was above their three months average volume of 6.57 million shares. The stock ended the session 2.20% lower at $5.79. The Company's shares have gained 5.95% in the previous three months. The stock is trading 16.84% above its 200-day moving average. Moreover, shares of Synergy Pharma, which focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases, have a Relative Strength Index (RSI) of 45.90. On February 07th, 2017, Synergy Pharmaceuticals announced that the American Journal of Gastroenterology has published detailed results from a pivotal Phase 3 trial that demonstrated the efficacy and safety of TRULANCE™ (plecanatide) for the treatment of adults with chronic idiopathic constipation (CIC).
On January 19th, 2017, TRULANCE was approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with CIC. TRULANCE is the first drug designed to replicate the function of uroguanylin, a naturally occurring and endogenous human gastrointestinal peptide that is thought to stimulate fluid secretion within the changing pH environment of the intestine. Access our complete research report on SGYP for free at:
http://stock-callers.com/registration/?symbol=SGYP
Novo Nordisk
Bagsvaerd, Denmark headquartered Novo Nordisk A/S' stock closed the day 1.15% lower at $35.33 with a total trading volume of 2.89 million shares. The Company's shares have advanced 10.13% over the previous three months. The stock is trading 0.17% below its 50-day moving average. Additionally, shares of Novo Nordisk, which engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide, have an RSI of 52.02.
On 28th, February 2017, Novo Nordisk announced the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labor, and Welfare for semaglutide, a new glucagon-like peptide-1 (GLP-1) analogue administrated once-weekly, for the treatment of adults with type-2 diabetes. The Japanese filing follows the recent once-weekly semaglutide regulatory submissions to the US FDA, the European Medicines Agency (EMA), Health Canada, and SwissMedic. The complimentary research report on NVO can be downloaded at:
http://stock-callers.com/registration/?symbol=NVO
Apricus Biosciences
Shares in San Diego, California headquartered Apricus Biosciences Inc. recorded a trading volume of 274,452 shares. The stock ended yesterday's trading session 7.94% lower at $2.90. The Company's shares have surged 21.85% in the past month, 89.54% in the previous three months, and 123.08% on an YTD basis. The stock is trading above its 50-day moving average by 37.60%. Furthermore, shares of Apricus Biosciences, which focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology, have an RSI of 58.74.
On February 09th, 2017, Apricus Biosciences announced that on February 08th, 2017, it was notified that the NASDAQ Hearings Panel has granted the Company`s request for continued listing on NASDAQ pursuant to an extension through May 30th, 2017, by which date the Company must evidence full compliance with all applicable criteria for continued listing on the NASDAQ Capital Market, including the $2.5 million stockholders` equity requirement. Register for free on Stock-Callers.com and get access to the latest PDF format report on APRI at:
http://stock-callers.com/registration/?symbol=APRI
Sucampo Pharma
Rockville, Maryland headquartered Sucampo Pharmaceuticals Inc.'s stock finished Tuesday's session 4.08% lower at $11.75. A total volume of 1.23 million shares was traded, which was above their three months average volume of 1.20 million shares. The Company's shares have advanced 5.86% in the last one month. The stock is trading below its 200-day moving average by 5.39%. Additionally, shares of Sucampo Pharma, which focuses on the research and development of proprietary drugs for the treatment of gastrointestinal, ophthalmic, autoimmune, and oncology-based inflammatory disorders in the US, Japan, Switzerland, and internationally, have an RSI of 47.60.
On February 23rd, 2017, Sucampo Pharmaceuticals announced that it will host its Q4 and full year 2016 financial results teleconference and webcast at 8:30 a.m. ET on Wednesday, March 08th, 2017. The press release announcing the financial results and operating highlights is expected to be released before the opening of capital markets on the same day. Download your free research report on SCMP at:
http://stock-callers.com/registration/?symbol=SCMP
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
